Jakko van Ingen

Summary

Affiliation: Radboud University Nijmegen Medical Centre
Country: The Netherlands

Publications

  1. ncbi request reprint The broad-spectrum antimycobacterial activities of phenothiazines, InVitro: somewhere in all of this there may be patentable potentials
    Jakko van Ingen
    Department of Clinical Microbiology 574, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    Recent Pat Antiinfect Drug Discov 6:104-9. 2011
  2. doi request reprint Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance
    Jakko van Ingen
    Department of Medical Microbiology, Radboud University Medical Center, P O Box 9101, 6500HB Nijmegen, The Netherlands
    Int J Antimicrob Agents 42:80-2. 2013
  3. pmc Education of phlebotomy teams improves blood volume in blood culture bottles
    Jakko van Ingen
    Department of Medical Microbiology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    J Clin Microbiol 51:1020-1. 2013
  4. doi request reprint The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment
    Jakko van Ingen
    Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, CO, USA
    Am J Respir Crit Care Med 186:559-65. 2012
  5. doi request reprint Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria
    Jakko van Ingen
    Department of Clinical Microbiology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    Drug Resist Updat 15:149-61. 2012
  6. doi request reprint Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated?
    Jakko van Ingen
    Department of Clinical Microbiology, Radboud University Nijmegen Medical Center, P O Box 9101, 6500 HB Nijmegen, The Netherlands
    Infect Genet Evol 12:832-7. 2012
  7. pmc Characterization of Mycobacterium orygis as M. tuberculosis complex subspecies
    Jakko van Ingen
    Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Emerg Infect Dis 18:653-5. 2012
  8. doi request reprint Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease
    Jakko van Ingen
    Division of Mycobacterial and Respiratory Infections, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA
    Int J Antimicrob Agents 39:173-6. 2012
  9. pmc Mycobacterium sherrisii sp. nov., a slow-growing non-chromogenic species
    Jakko van Ingen
    Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Int J Syst Evol Microbiol 61:1293-8. 2011
  10. doi request reprint Mycobacterium noviomagense sp. nov.; clinical relevance evaluated in 17 patients
    Jakko van Ingen
    Radboud University Nijmegen Medical Center, Department of Pulmonary Diseases, Nijmegen, The Netherlands
    Int J Syst Evol Microbiol 59:845-9. 2009

Detail Information

Publications25

  1. ncbi request reprint The broad-spectrum antimycobacterial activities of phenothiazines, InVitro: somewhere in all of this there may be patentable potentials
    Jakko van Ingen
    Department of Clinical Microbiology 574, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    Recent Pat Antiinfect Drug Discov 6:104-9. 2011
    ..New drugs for treatment of mycobacterial disease, most notable multidrug- and extensively drug-resistant tuberculosis, are urgently needed; phenothiazines and their targets should be exploited for this use...
  2. doi request reprint Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance
    Jakko van Ingen
    Department of Medical Microbiology, Radboud University Medical Center, P O Box 9101, 6500HB Nijmegen, The Netherlands
    Int J Antimicrob Agents 42:80-2. 2013
    ..New dosing strategies for rifampicin and ethambutol should be studied to increase the exposure to these drugs and thus maximise their impact...
  3. pmc Education of phlebotomy teams improves blood volume in blood culture bottles
    Jakko van Ingen
    Department of Medical Microbiology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    J Clin Microbiol 51:1020-1. 2013
    ..77 ± 4.42 ml) and anaerobic (8.30 ± 3.64 ml) bottles. Education of phlebotomy teams improves the blood volume in blood culture bottles and should be part of quality control procedures...
  4. doi request reprint The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment
    Jakko van Ingen
    Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, CO, USA
    Am J Respir Crit Care Med 186:559-65. 2012
    ..Currently recommended multidrug treatment regimens for Mycobacterium avium complex (MAC) lung disease yield limited cure rates. This results, in part, from incomplete understanding of the pharmacokinetics and pharmacodynamics of the drugs...
  5. doi request reprint Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria
    Jakko van Ingen
    Department of Clinical Microbiology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    Drug Resist Updat 15:149-61. 2012
    ..This review provides a comprehensive overview of the mechanisms of drug resistance in NTM, phenotypic methods for testing susceptibility in past and current use for DST of NTM, as well as molecular approaches to assess drug resistance...
  6. doi request reprint Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated?
    Jakko van Ingen
    Department of Clinical Microbiology, Radboud University Nijmegen Medical Center, P O Box 9101, 6500 HB Nijmegen, The Netherlands
    Infect Genet Evol 12:832-7. 2012
    ....
  7. pmc Characterization of Mycobacterium orygis as M. tuberculosis complex subspecies
    Jakko van Ingen
    Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Emerg Infect Dis 18:653-5. 2012
    ..We characterized 22 isolates by molecular methods and propose elevation to subspecies status as M. orygis. M. orygis is a causative agent of tuberculosis in animals and humans from Africa and South Asia...
  8. doi request reprint Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease
    Jakko van Ingen
    Division of Mycobacterial and Respiratory Infections, National Jewish Health, 1400 Jackson Street, Denver, CO 80206, USA
    Int J Antimicrob Agents 39:173-6. 2012
    ..simiae disease. A treatment regimen including a macrolide, moxifloxacin and one or two additional drugs based on DST results may be advisable; clofazimine and amikacin or streptomycin are potential candidates...
  9. pmc Mycobacterium sherrisii sp. nov., a slow-growing non-chromogenic species
    Jakko van Ingen
    Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Int J Syst Evol Microbiol 61:1293-8. 2011
    ..5 % (391/401 bp) and 95.2 % (700/735 bp), respectively. On the basis of these results, we propose the formal recognition of Mycobacterium sherrisii sp. nov. The type strain is 4773(T) ( = ATCC BAA-832(T) = DSM 45441(T))...
  10. doi request reprint Mycobacterium noviomagense sp. nov.; clinical relevance evaluated in 17 patients
    Jakko van Ingen
    Radboud University Nijmegen Medical Center, Department of Pulmonary Diseases, Nijmegen, The Netherlands
    Int J Syst Evol Microbiol 59:845-9. 2009
    ..nov. is proposed for the novel strains. The type strain is NLA000500338(T) (=DSM 45145(T)=CIP 109766(T)). A more distinctive taxonomy of NTM is a prerequisite for the assessment of their clinical relevance...
  11. doi request reprint Mycobacterium mantenii sp. nov., a pathogenic, slowly growing, scotochromogenic species
    Jakko van Ingen
    Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Int J Syst Evol Microbiol 59:2782-7. 2009
    ..We propose the name Mycobacterium mantenii sp. nov. for this novel species. The type strain, isolated from a lymph node biopsy sample, is strain 04-1474(T) (=NLA000401474(T) =CIP 109863(T) =DSM 45255(T))...
  12. pmc In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease
    Jakko van Ingen
    Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, CO, USA
    Antimicrob Agents Chemother 56:6324-7. 2012
    ..Synergy between clofazimine and other antibiotics with intracellular targets should be explored...
  13. pmc Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide
    Sami O Simons
    Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Clin Microbiol 50:428-34. 2012
    ....
  14. ncbi request reprint [Nontuberculous mycobacteria: clinically relevant]
    Jakko van Ingen
    Radboud Universiteit Nijmegen Medisch Centrum, afd Longziekten, Nijmegen, en Universitair Centrum voor Chronische Ziekten Dekkerswald, Groesbeek, The Netherlands
    Ned Tijdschr Geneeskd 154:A1178. 2010
    ..Therefore, prompt consultation with one of the specialized centres of expertise is warranted. We should also consider formulating national guidelines for diagnosis and treatment...
  15. doi request reprint Clinical relevance of Mycobacterium szulgai in The Netherlands
    Jakko van Ingen
    Department of Pulmonary Diseases, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    Clin Infect Dis 46:1200-5. 2008
    ..The clinical relevance of Mycobacterium szulgai isolates is unknown, and available literature focuses on case reports of M. szulgai disease. We assessed the clinical relevance of M. szulgai isolated from patients in The Netherlands...
  16. doi request reprint Low rate of fluoroquinolone resistance in Mycobacterium tuberculosis isolates from northern Tanzania
    Jossy van den Boogaard
    Radboud University Nijmegen Medical Centre, University Centre for Chronic Diseases Dekkerswald, PO Box 66, 6560 AB, Groesbeek, The Netherlands
    J Antimicrob Chemother 66:1810-4. 2011
    ..We determined the rate of fluoroquinolone resistance in M. tuberculosis isolates obtained from Tanzanian patients and linked this to previous fluoroquinolone exposure and mycobacterial resistance to rifampicin and isoniazid...
  17. doi request reprint In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands
    Jakko van Ingen
    Department of Pulmonary Diseases, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    Int J Antimicrob Agents 35:169-73. 2010
    ..To improve the utility of drug susceptibility testing, the selection of drugs should be changed to more drugs with proven clinical efficacy correlating with in vitro susceptibility...
  18. pmc Mycobacterium xenopi clinical relevance and determinants, the Netherlands
    Jakko van Ingen
    Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    Emerg Infect Dis 14:385-9. 2008
    ..Most infections were pulmonary, but pleural and spinal infections (spinal in HIV-infected patients) were also noted. Treatment regimens varied in content and duration; some patients were over-treated and some were undertreated...
  19. doi request reprint Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?
    Jakko van Ingen
    University Center for Chronic Diseases Dekkerswald and Department of Pulmonary Diseases, Radboud University Nijmegen MedicalCenter, Nijmegen, The Netherlands
    Clin Infect Dis 52:e194-9. 2011
    ..The reduced cost and the lack of evidence of toxicity at higher daily doses remove the other arguments. To optimize tuberculosis treatment, the clinical value of higher doses of rifampicin should be tested in clinical trials...
  20. doi request reprint Mycobacterial disease in patients with rheumatic disease
    Jakko van Ingen
    Respiratory Diseases Department, Radboud University Nijmegen Medical Center, The Netherlands
    Nat Clin Pract Rheumatol 4:649-56. 2008
    ..Further studies are needed to determine the prevalence of NTM disease in this setting, and to evaluate the safety of simultaneous anti-TNF and antimycobacterial treatment...
  21. ncbi request reprint Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy
    Jakko van Ingen
    Department of Pulmonary Diseases, Radboud University, Nijmegen Medical Centre, and the Rijnstate Hospital in Arnhem, The Netherlands
    Nat Clin Pract Rheumatol 3:414-9. 2007
    ..His medication at presentation consisted of etanercept, azathioprine, naproxen and inhaled fluticasone and salbutamol...
  22. pmc Nontuberculous mycobacteria in respiratory tract infections, eastern Asia
    Sami Simons
    Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Emerg Infect Dis 17:343-9. 2011
    ..This geographic variation is not well reflected in the American Thoracic Society criteria for NTM infections and could be incorporated in future guidelines...
  23. doi request reprint Clinical relevance of Mycobacterium chelonae-abscessus group isolation in 95 patients
    Jakko van Ingen
    Department of Pulmonary Diseases, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    J Infect 59:324-31. 2009
    ..To determine the clinical relevance of Mycobacterium chelonae-abscessus group isolation from clinical samples...
  24. doi request reprint Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence
    Jakko van Ingen
    Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands
    Expert Rev Anti Infect Ther 11:1065-77. 2013
    ..From the data of these trials and case series, we reconstruct a more evidence-based overview of possible drug treatment regimens and their outcomes. ..
  25. pmc Otomastoiditis Caused by Mycobacterium abscessus, the Netherlands
    Jakko van Ingen
    Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands J van Ingen, F Looijmans, R Dekhuijzen, M Boeree National Institute for Public Health and the Environment, Bilthoven, the Netherlands J van Ingen, D van Soolingen and Academic Medical Centre, Amsterdam, the Netherlands P Mirck
    Emerg Infect Dis 16:166-8. 2010
    ....